Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

被引:44
作者
Poettgen, Christoph [1 ]
Theegarten, Dirk [5 ]
Eberhardt, Wilfried [2 ]
Levegruen, Sabine [1 ]
Gauler, Thomas [2 ]
Krbek, Thomas
Stamatis, Georgios [6 ]
Teschler, Helmut [7 ]
Kuehl, Hilmar [3 ]
Bockisch, Andreas [4 ]
Stuschke, Martin [1 ]
机构
[1] Univ Duisburg Essen, Dept Radiotherapy, DE-45122 Essen, Germany
[2] Univ Duisburg Essen, Dept Intenal Med Canc Res, DE-45122 Essen, Germany
[3] Univ Duisburg Essen, Dept Diagnost & Intervent Radiol, DE-45122 Essen, Germany
[4] Univ Duisburg Essen, Dept Nucl Med, DE-45122 Essen, Germany
[5] Univ Duisburg Essen, Inst Pathol & Neuropathol, DE-45122 Essen, Germany
[6] Univ Duisburg Essen, Dept Thorac Surg, DE-45122 Essen, Germany
[7] Univ Duisburg Essen, Dept Pulmonol, DE-45122 Essen, Germany
关键词
chemoradiotherapy; dual-modality PET/CT; locally advanced non-small cell lung cancer; macrophage infiltration; neoadjuvant;
D O I
10.1159/000134474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods: F-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/ 45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4-9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV > 2.5 and volumes larger than the median (7.9 cm(3)) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 50 条
  • [31] Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands
    Joosten, Pieter J. M.
    Damhuis, Ronald A. M.
    van Diessen, Judi N. A.
    de Langen, Joop A.
    Belderbos, Jose S. A.
    Smit, Egbert F.
    Klomp, Houke M.
    Veenhof, Alexander A. F. A.
    Hartemink, Koen J.
    ACTA ONCOLOGICA, 2020, 59 (07) : 748 - 752
  • [32] Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer
    Zhao, D.
    Wu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S295 - S296
  • [33] The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents
    Sposito, Marco
    Eccher, Serena
    Scaglione, Ilaria
    Avancini, Alice
    Rossi, Antonio
    Pilotto, Sara
    Belluomini, Lorenzo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, : 1025 - 1037
  • [34] FDG PET Scan Based Response Assesment in Non-Small Cell Lung Cancer Treated With Chemoradiotherapy And Neoadjuvant Chemotherapy
    Ahmad, A.
    Majumdar, S. K. D.
    Parida, D. K.
    Barik, S. K.
    Das, D. K.
    Bagul, D. Y.
    Shaikh, L.
    Amin, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S571 - S571
  • [35] Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
    Bott, Matthew J.
    Yang, Stephen C.
    Park, Bernard J.
    Adusumilli, Prasad S.
    Rusch, Valerie W.
    Isbell, James M.
    Downey, Robert J.
    Brahmer, Julie R.
    Battafarano, Richard
    Bush, Errol
    Chaft, Jamie
    Forde, Patrick M.
    Jones, David R.
    Broderick, Stephen R.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 158 (01) : 269 - 275
  • [36] Risk factors for pulmonary complications after neoadjuvant chemoradiotherapy followed by surgery for non-small cell lung cancer
    Kim, Ha Eun
    Yu, Woo Sik
    Lee, Chang Young
    Lee, Jin Gu
    Kim, Dae Joon
    Park, Seong Yong
    THORACIC CANCER, 2022, 13 (03) : 361 - 368
  • [37] The Role of Salvage Resection After Definitive Radiation Therapy for Non-small Cell Lung Cancer
    Rosenstein, Allison L.
    Potter, Alexandra L.
    Senthil, Priyanka
    Raman, Vignesh
    Kumar, Arvind
    Muniappan, Ashok
    Berry, Mark F.
    Yang, Chi-Fu Jeffrey
    ANNALS OF THORACIC SURGERY, 2023, 116 (05) : 997 - 1003
  • [38] Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
    Aguado, Carlos
    Chara, Luis
    Antonanzas, Monica
    Matilla Gonzalez, Jose Maria
    Jimenez, Unai
    Hernanz, Raul
    Mielgo-Rubio, Xabier
    Trujillo-Reyes, Juan Carlos
    Counago, Felipe
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (05): : 314 - 322
  • [39] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [40] Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer
    Kayawake, Hidenao
    Okumura, Norihito
    Yamanashi, Keiji
    Otsuki, Yasuhiro
    Takahashi, Ayuko
    Itasaka, Satoshi
    Yoshioka, Hiroshige
    Nakashima, Takashi
    Matsuoka, Tomoaki
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2018, 66 (11) : 658 - 663